Ken Griffin Bio N Tech Se Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio N Tech Se stock. As of the latest transaction made, Citadel Advisors LLC holds 135,600 shares of BNTX stock, worth $14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
135,600
Previous 374,400
63.78%
Holding current value
$14 Million
Previous $34.1 Million
57.65%
% of portfolio
0.0%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding BNTX
# of Institutions
319Shares Held
40.9MCall Options Held
1.38MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$832 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$438 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$414 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$372 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$196 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.1B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...